News

Metreleptin was granted orphan drug designation by the European Commission in July 2012, and if approved, carries 10 years of exclusivity in the EU. The company estimates the

The primary endpoint of incidence of DGF with a two-dose regimen of eculizumab compared with placebo did not reach statistical significance. DGF is an early and serious complication

Patients receiving emicizumab showed a statistically significant reduction in bleeds over time compared with those not being treated with it. The treatment also met secondary goals of reducing

A portfolio of NADPH oxidase (NOX) oral small molecule inhibitors are being developed by Genkyotex, which have therapeutic potential to treat multiple significant clinical indications. The therapeutic approach

After one or two vaccinations, subjects who were previously not affected by Zika showed antigen-specific antibody responses to the virus during initial testing in both low dose and

Cerdulatinib is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that Portola is developing to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib is

The Collaboration and License Agreement grants Incyte the exclusive rights for up to eleven bispecific antibody research programs, including two of Merus’ current preclinical immuno-oncology discovery programs. Biclonics

This acquisition would add a first-in-class disease modifying topical treatment for presbyopia to the Novartis ophthalmology pipeline, providing a potentially disruptive innovation to patients in a new therapeutic

The phase 2 study, dubbed Hermione, evaluated MM-302, an antibody-targeted liposomal doxorubicin, in HER2-positive metastatic breast cancer patients who had earlier been treated with trastuzumab (Herceptin), pertuzumab (Perjeta)